Axial Spondyloarthritis Market Growth Strategies & Future Scope
2022-09-02 • bis research
The global axial spondyloarthritis market is expected to witness high growth, attributed to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis. The continued significant investments by the emerging and legacy companies to meet industry demand and the growing adoption of novel therapeutics by rheumatologists are the major factors propelling the growth of the global axial spondyloarthritis market.
The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032. The growth in the global axial spondyloarthritis market is expected to be driven by the introduction of novel products, the increasing awareness about the disease, and the rising research and development investments, among others.
There has been a rise in research and development of novel medications in the rheumatology field. The development of the classification criteria for axial spondyloarthritis (axSpA) through Assessment in Spondyloarthritis International Society (ASAS) has led to major breakthroughs in medications over the past decade. In the past three decades, progress in molecular and immunologic research has repeatedly pointed to cytokine dysregulation as a critical factor in the pathophysiology of autoimmune and autoinflammatory diseases, including axSpA.
EXPERT INSIGHT by Khalid Shirazy Rheumatologist on Axial Spondyloarthritis Market
ANALYST – How is your work related to the axial spondyloarthritis market?